FDA Approves AstraZeneca and Daiichi Sankyo's ENHERTU Regimen for HER2-Positive Metastatic Breast Cancer
I'm PortAI, I can summarize articles.
AstraZeneca and Daiichi Sankyo's ENHERTU regimen for HER2-positive metastatic breast cancer has been approved by the FDA in the US. The approval was expedited under the FDA's RTOR initiative and reviewed under Project Orbis. AstraZeneca will pay Daiichi Sankyo a $150 million milestone following this approval. The news was generated by Public Technologies using AI and is based on AstraZeneca's original content.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments